{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T15:01:33Z","timestamp":1768662093864,"version":"3.49.0"},"reference-count":31,"publisher":"Japanese Society of Veterinary Science","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Vet. Med. Sci.","The Journal of Veterinary Medical Science"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1292\/jvms.25-0478","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T22:08:42Z","timestamp":1763676522000},"page":"119-125","source":"Crossref","is-referenced-by-count":0,"title":["Combination effect of Exportin 1 inhibitor (KPT-335) with doxorubicin or vincristine in canine lymphoma cell          lines"],"prefix":"10.1292","volume":"88","author":[{"given":"Hardany","family":"PRIMARIZKY","sequence":"first","affiliation":[{"name":"Laboratory of Veterinary Internal Medicine, Joint Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi,              Japan"},{"name":"Veterinary Clinical Division, Department of Veterinary Science, Faculty of Veterinary Medicine, Universitas Airlangga,              Surabaya, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"KAMBAYASHI","sequence":"additional","affiliation":[{"name":"Laboratory of Veterinary Internal Medicine, Joint Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi,              Japan"},{"name":"Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi,              Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"BABA","sequence":"additional","affiliation":[{"name":"Laboratory of Veterinary Internal Medicine, Joint Graduate School of Veterinary Medicine, Yamaguchi University, Yamaguchi,              Japan"},{"name":"Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi,              Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"TANI","sequence":"additional","affiliation":[{"name":"Laboratory of Veterinary Surgery, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"OKUDA","sequence":"additional","affiliation":[{"name":"Laboratory of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo,              Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"122","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Azizian              NG, Li              Y. 2020. XPO1-dependent nuclear export as a target            for cancer therapy. <i>J Hematol Oncol<\/i>          13: 61.","DOI":"10.1186\/s13045-020-00903-4"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Balasubramanian              SK, Azmi              AS, Maciejewski              J. 2022. Selective inhibition of nuclear export: a            promising approach in the shifting treatment paradigms for hematological neoplasms.            <i>Leukemia<\/i>          36: 601\u2013612.","DOI":"10.1038\/s41375-021-01483-z"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Breitbach              JT, Louke              DS, Tobin              SJ, Watts              MR, Davies              AE, Fenger              JM. 2021. The selective inhibitor of nuclear export            (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines. <i>Vet Comp              Oncol<\/i>          19: 362\u2013373.","DOI":"10.1111\/vco.12680"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Breit              MN, Kisseberth              WC, Bear              MD, Landesman              Y, Kashyap              T, McCauley              D, Kauffman              MG, Shacham              S, London              CA. 2014. Biologic activity of the novel orally            bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines. <i>BMC              Vet Res<\/i>          10: 160.","DOI":"10.1186\/1746-6148-10-160"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Chao              MW, Lai              MJ, Liou              JP, Chang              YL, Wang              JC, Pan              SL, Teng              CM. 2015. The synergic effect of vincristine and            vorinostat in leukemia in vitro and in vivo. <i>J Hematol Oncol<\/i>          8: 82.","DOI":"10.1186\/s13045-015-0176-7"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Chou              TC. 2010. Drug combination studies and their synergy            quantification using the Chou-Talalay method. <i>Cancer Res<\/i>          70: 440\u2013446.","DOI":"10.1158\/0008-5472.CAN-09-1947"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Fisher              JG, Bartlett              LG, Kashyap              T, Walker              CJ, Khakoo              SI, Blunt              MD. 2025. Modulation of anti-tumour immunity by XPO1            inhibitors. <i>Explor Target Antitumor Ther<\/i>          6: 1002310.","DOI":"10.37349\/etat.2025.1002310"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Galinski              B, Luxemburg              M, Landesman              Y, Pawel              B, Johnson              KJ, Master              SR, Freeman              KW, Loeb              DM, H\u00e9bert              JM, Weiser              DA. 2021. XPO1 inhibition with selinexor synergizes            with proteasome inhibition in neuroblastoma by targeting nuclear export of IkB. <i>Transl            Oncol<\/i>          14: 101114.","DOI":"10.1016\/j.tranon.2021.101114"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Gravina              GL, Senapedis              W, McCauley              D, Baloglu              E, Shacham              S, Festuccia              C. 2014. Nucleo-cytoplasmic transport as a            therapeutic target of cancer. <i>J Hematol Oncol<\/i>          7: 85.","DOI":"10.1186\/s13045-014-0085-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hantrakul              S, Klangkaew              N, Kunakornsawat              S, Tansatit              T, Poapolathep              A, Kumagai              S, Poapolathep              S. 2014. Clinical pharmacokinetics and effects of            vincristine sulfate in dogs with transmissible venereal tumor (TVT). <i>J Vet Med Sci<\/i>          76: 1549\u20131553.","DOI":"10.1292\/jvms.14-0180"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kos              IA, Thurner              L, Bittenbring              JT, Christofyllakis              K, Kaddu-Mulindwa              D. 2021. Advances in Lymphoma Molecular            Diagnostics. <i>Diagnostics (Basel)<\/i>          11: 2174.","DOI":"10.3390\/diagnostics11122174"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lewin              J, Malone              E, Al-Ezzi              E, Fasih              S, Pedersen              P, Accardi              S, Gupta              A, Abdul Razak              A. 2021. A phase 1b trial of selinexor, a            first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue            sarcomas (STS). <i>Eur J Cancer<\/i>          144: 360\u2013367.","DOI":"10.1016\/j.ejca.2020.10.032"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. London              CA, Bernabe              LF, Barnard              S, Kisseberth              WC, Borgatti              A, Henson              M, Wilson              H, Jensen              K, Ito              D, Modiano              JF, Bear              MD, Pennell              ML, Saint-Martin              JR, McCauley              D, Kauffman              M, Shacham              S. 2014. Preclinical evaluation of the novel, orally            bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I          study. <i>PLoS One<\/i>          9: e87585.","DOI":"10.1371\/journal.pone.0087585"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ou              L, Wang              X, Cheng              S, Zhang              M, Cui              R, Hu              C, Liu              S, Tang              Q, Peng              Y, Chai              R, Xie              S, Wang              S, Huang              W, Wang              X. 2022. Verdinexor, a selective inhibitor of            nuclear Exportin 1, inhibits the proliferation and migration of esophageal cancer via XPO1\/c-Myc\/FOSL1 axis.              <i>Int J Biol Sci<\/i>          18: 276\u2013291.","DOI":"10.7150\/ijbs.66612"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. \u00d6zda\u015f              S, Canatar              \u0130. 2021. Targeting of nucleo\u2011cytoplasmic transport            factor exportin 1 in malignancy (Review)          (Review). <i>Med Int (Lond)<\/i>          2: 2.","DOI":"10.3892\/mi.2021.27"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Pan              L, Cheng              C, Duan              P, Chen              K, Wu              Y, Wu              Z. 2021. XPO1\/CRM1 is a promising prognostic            indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor. <i>J Exp              Clin Cancer Res<\/i>          40: 255.","DOI":"10.1186\/s13046-021-02044-z"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Primarizky              H, Kambayashi              S, Baba              K, Tani              K, Okuda              M. 2025. Exportin 1 (XPO1) expression and            effectiveness of XPO1 inhibitor against canine lymphoma cell lines. <i>Vet Sci<\/i>          12: 700.","DOI":"10.3390\/vetsci12080700"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Sadowski              AR, Gardner              HL, Borgatti              A, Wilson              H, Vail              DM, Lachowicz              J, Manley              C, Turner              A, Klein              MK, Waite              A, Sahora              A, London              CA. 2018. Phase II study of the oral selective            inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. <i>BMC Vet            Res<\/i>          14: 250.","DOI":"10.1186\/s12917-018-1587-9"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Senapedis              WT, Baloglu              E, Landesman              Y. 2014. Clinical translation of nuclear export            inhibitors in cancer. <i>Semin Cancer Biol<\/i>          27: 74\u201386.","DOI":"10.1016\/j.semcancer.2014.04.005"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. \u0160kubn\u00edk              J, Pavl\u00ed\u010dkov\u00e1              VS, Ruml              T, Rimpelov\u00e1              S. 2021. Vincristine in combination therapy of            cancer: emerging trends in clinics. <i>Biology (Basel)<\/i>          10: 849.","DOI":"10.3390\/biology10090849"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Turner              JG, Dawson              J, Cubitt              CL, Baz              R, Sullivan              DM. 2014. Inhibition of CRM1-dependent nuclear            export sensitizes malignant cells to cytotoxic and targeted agents. <i>Semin Cancer Biol<\/i>          27: 62\u201373.","DOI":"10.1016\/j.semcancer.2014.03.001"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Turner              JG, Dawson              J, Emmons              MF, Cubitt              CL, Kauffman              M, Shacham              S, Hazlehurst              LA, Sullivan              DM. 2013. CRM1 inhibition sensitizes drug resistant            human myeloma cells to Topoisomerase II and proteasome inhibitors both in vitro and ex vivo. <i>J              Cancer<\/i>          4: 614\u2013625.","DOI":"10.7150\/jca.7080"},{"key":"23","unstructured":"23. Vail              DM, Pinkerton              ME, Young              KM. 2013. Canine lymphoma and lymphoid leukemias. pp. 608\u2013631. In:          Withrow and MacEwen\u2019s Small Animal Clinical Oncology, 5th ed. (Withrow SJ, Vail DM, Page RL eds), Elsevier, St. Louis."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Valli              VE, Kass              PH, San Myint              M, Scott              F. 2013. Canine lymphomas: association of            classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival. <i>Vet              Pathol<\/i>          50: 738\u2013748.","DOI":"10.1177\/0300985813478210"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Vlodaver              EM, Keating              MK, Bidot              WA, Bruyette              DS, Rosenkrantz              WS. 2024. Efficacy of verdinexor for the treatment            of na\u00efve canine epitheliotropic cutaneous T-cell lymphoma: An open-label pilot study. <i>Vet              Dermatol<\/i>          35: 536\u2013546.","DOI":"10.1111\/vde.13280"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Wang              J, Chen              M, Jiang              J, Wan              Y, Li              X, Zhang              M, Xiao              F, Zhong              L, Zhong              H, Qin              Z, Hou              J. 2025. Targeting deubiquitinase USP7-mediated            stabilization of XPO1 contributes to the anti-myeloma effects of selinexor. <i>J Transl Med<\/i>          23: 62.","DOI":"10.1186\/s12967-025-06068-3"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Wittenburg              LA, Weishaar              K, Ramirez              D, Gustafson              DL. 2019. Doxorubicin area under the curve is an            important predictor of neutropenia in dogs with naturally occurring cancers. <i>Vet Comp            Oncol<\/i>          17: 147\u2013154.","DOI":"10.1111\/vco.12455"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Wolf-Ringwall              A, Lopez              L, Elmslie              R, Fowler              B, Lori              J, Sfiligoi              G, Skope              A, Arnold              E, Hughes              KL, Thamm              DH, Ehrhart              EJ              3rd, Avery              AC, Lana              SE. 2020. Prospective evaluation of flow cytometric            characteristics, histopathologic diagnosis and clinical outcome in dogs with na\u00efve B-cell lymphoma treated with a 19-week CHOP            protocol. <i>Vet Comp Oncol<\/i>          18: 342\u2013352.","DOI":"10.1111\/vco.12553"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Yang              YT, Yuzbasiyan-Gurkan              V. 2022. Sorafenib and doxorubicin show synergistic            effects in human and canine osteosarcoma cell lines. <i>Int J Mol Sci<\/i>          23: 9345.","DOI":"10.3390\/ijms23169345"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Zandvliet              M. 2016. Canine lymphoma: a review.              <i>Vet Q<\/i>          36: 76\u2013104.","DOI":"10.1080\/01652176.2016.1152633"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Zhao              C, Yang              ZY, Zhang              J, Li              O, Liu              SL, Cai              C, Shu              YJ, Pan              LJ, Gong              W, Dong              P. 2022. Inhibition of XPO1 with KPT-330 induces            autophagy-dependent apoptosis in gallbladder cancer by activating the p53\/mTOR pathway. <i>J Transl              Med<\/i>          20: 434.","DOI":"10.1186\/s12967-022-03635-w"}],"container-title":["Journal of Veterinary Medical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jvms\/88\/1\/88_25-0478\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T03:45:01Z","timestamp":1768621501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jvms\/88\/1\/88_25-0478\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1292\/jvms.25-0478","relation":{},"ISSN":["0916-7250","1347-7439"],"issn-type":[{"value":"0916-7250","type":"print"},{"value":"1347-7439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"25-0478"}}